2020 Pharmacology Safety 
European Pharmaceutical Review
JULY 4, 2024
The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. 10,12 The THR scheme is also limited to products used for oral or external use and/or inhalation.
Pharmaceutical Technology
FEBRUARY 8, 2023
In 2020, the FDA released a guidance document for the industry with recommendations for sponsors developing gene therapies for rare diseases. Still, Blank suggested that companies enroll the patient population that is most likely to benefit, because early phase studies contain the most safety risks.
Pharmaceutical Representative Training
JUNE 22, 2024
The pharmaceutical industry is one of the most heavily regulated sectors due to the direct impact of its products on public health and safety. Several factors contribute to the stringent regulatory environment: Patient Safety: Ensuring that the pharmaceutical products are safe and effective is a crucial aspect.
Impetus Digital
AUGUST 2, 2024
In 2020, McKinsey estimated that over the next 3–5 years, the average top-20 Big Pharma company could unlock over $300 million a year by adopting advanced RWE analytics across its value chain. To avoid compliance issues , it is essential to keep up with new regulatory changes, including updated reporting guidelines and safety requirements.
pharmaphorum
DECEMBER 22, 2022
If approved, etrasimod will mount a direct challenge to Bristol-Myers Squibb’s S1P drug Zeposia (ozanimod), which was approved for UC last year and also for a green light to treat multiple sclerosis in 2020. “We believe that etrasimod, if approved, has the potential to be a best-in-class, first-line advanced therapy.”
European Pharmaceutical Review
SEPTEMBER 22, 2023
7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.
Legacy MEDSearch
AUGUST 25, 2022
The primary safety endpoint is a performance goal for device and procedure related adverse events at 30 days. The FDA-approved randomized IDE trial has been designed to validate the safety and effectiveness of PiCSO.” The PiCSO Impulse System received ‘Breakthrough Designation’ from the FDA in 2019 and the CE-Mark in 2020.
Expert insights. Personalized for you.
103 
Let's personalize your content